Trial Profile
A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog) in Patients With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin lispro (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Halozyme Therapeutics
- 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Jul 2013 Planned end date changed from 1 Dec 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 11 Sep 2012 Planned End Date changed from 1 Sep 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.